Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: A multi-institutional phase II trial

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4369-4373

  Ichinose, Yukito ^a,j   Nakai, Yushi ^b   Kudoh, Shoji ^c   Semba, Hiroshi ^d   Yoshida, Susumu ^e   Nukiwa, Toshihiro ^f   Yamamoto, Hidehiko ^g   Yamane, Yoshio ^h   Niitani, Hisanobu ⁱ  

^a National Hospital Organization   (Japan)

^b Sendai Kohsei Hospital   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

^e Takeda General Hospital   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

^g ASO IIZUKA HOSPITAL   (Japan)

^h Iwaki Kyoritsu Hospital   (Japan)

ⁱ Tokyo Cooperative Oncology Group   (Japan)

^j NATIONAL KYUSHU CANCER CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PREDNISOLONE; UFT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DYSPNEA; ESOPHAGITIS; FEMALE; HEMATURIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RADIATION DOSE; RADIATION PNEUMONIA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; SEX FACTORS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME; URACIL;

EID: 3042776796     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0143     Document Type: Article

References (23)

1. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
2. Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003;123(Suppl 1):221S-5S.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
4. Curran W, Scott C, Langer C. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 2000;29(Suppl 1):93.
5. Heim W, Wampler GL, Lokich JJ, et al. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. J Clin Oncol 1991;9:2162-6.
6. Ichinose Y, Takanashi N, Yano T, et al. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer (Phila) 1995;75:2677-80.
7. Ichinose Y, Yosimori K, Yoneda S, Kuba M, Kudoh S, Niitani H. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group. Cancer (Phila) 2000;88:318-23.
8. Saito J, Nakai Y, Saijo Y, et al. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC). Lung Cancer 2001;31:285-93.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
10. Douple EB, Richmond RC. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys 1982;8:501-3.
11. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33.
12. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
13. Lo TC, Wiley AL Jr, Ansfield FJ, et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976;126:229-35.
14. Segawa Y, Ueoka H, Kiura K, et al. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 2000;82:104-11.
15. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
16. Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998;4:2085-8.
17. Yoshino I, Yohena T, Kitajima M, et al. UFr plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2000;19:506a.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer (Phila) 1981;47:207-14.
19. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
20. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-60.
21. Hoff PM, Janjan N, Saad ED, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000;18:3529-34.
22. de la Torre A, Ramos S, Valcarcel FJ, et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1999;45:629-34.
23. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-10.